Antiretroviral therapy coverage for PMTCT in Suriname

Suriname: Antiretroviral therapy coverage for PMTCT was 66.0% in 2024. ◆ Volatile

Latest (2024)
66.0%
Change on year
unchanged
World rank
56th
of 84 countries
All-time high
86.0%
in 2015
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Suriname, 2000–2024

0204060802000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 0 % of pregnant women living with HIV2003: 2 % of pregnant women living with HIV2004: 12 % of pregnant women living with HIV2005: 35 % of pregnant women living with HIV2006: 49 % of pregnant women living with HIV2007: 65 % of pregnant women living with HIV2008: 61 % of pregnant women living with HIV2009: 58 % of pregnant women living with HIV2010: 54 % of pregnant women living with HIV2011: 79 % of pregnant women living with HIV2012: 77 % of pregnant women living with HIV2013: 75 % of pregnant women living with HIV2014: 78 % of pregnant women living with HIV2015: 86 % of pregnant women living with HIV2016: 76 % of pregnant women living with HIV2017: 68 % of pregnant women living with HIV2018: 67 % of pregnant women living with HIV2019: 65 % of pregnant women living with HIV2020: 72 % of pregnant women living with HIV2021: 68 % of pregnant women living with HIV2022: 69 % of pregnant women living with HIV2023: 66 % of pregnant women living with HIV2024: 66 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

Suriname recorded 66.0% for antiretroviral therapy coverage for pmtct in 2024.

The figure is down 15.4% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Suriname peaked at 86.0% in 2015 and was at its lowest, 0.0%, in 2000.

That places Suriname 56th out of 84 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Suriname, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Suriname, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 2.0%
2004 12.0% +500.0%
2005 35.0% +191.7%
2006 49.0% +40.0%
2007 65.0% +32.7%
2008 61.0% -6.2%
2009 58.0% -4.9%
2010 54.0% -6.9%
2011 79.0% +46.3%
2012 77.0% -2.5%
2013 75.0% -2.6%
2014 78.0% +4.0%
2015 86.0% +10.3%
2016 76.0% -11.6%
2017 68.0% -10.5%
2018 67.0% -1.5%
2019 65.0% -3.0%
2020 72.0% +10.8%
2021 68.0% -5.6%
2022 69.0% +1.5%
2023 66.0% -4.3%
2024 66.0% +0.0%

Suriname compared with similar countries

  • Suriname's 66.0% is below the median for upper middle income countries, which is 79.5%, 83% of the median. (22 countries reporting)
  • Suriname's 66.0% is below the median for Latin America & Caribbean, which is 68.0%, 97% of the median. (15 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Suriname changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2004 +500.0% 2.0% 12.0%
2005 +191.7% 12.0% 35.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 28.2% 0.0% 65.0% 10
2010s 72.5% 54.0% 86.0% 10
2020s 68.2% 66.0% 72.0% 5

Countries ranked near Suriname

  1. 54 Dominican Republic 68.0% compare
  2. 54 Laos 68.0% compare
  3. 56 El Salvador 66.0% compare
  4. 58 Burundi 65.0% compare
  5. 58 Nepal 65.0% compare

See the full ranking of 99 places →

More health data for Suriname

All data for Suriname →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Suriname?
Antiretroviral therapy coverage for pmtct in Suriname was 66.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Suriname?
The highest recorded value was 86.0% in 2015.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Suriname?
The lowest recorded value was 0.0% in 2000.
How does Suriname rank for antiretroviral therapy coverage for pmtct?
Suriname ranks 56th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Suriname?
Over the last ten years it is down 15.4%. The long-run trend across the full record is volatile.
Where does this Suriname data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Suriname. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 18 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/suriname/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/suriname/">Antiretroviral therapy coverage for PMTCT in Suriname</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).